Naldemedine: First Global Approval
Related Experiment Video
Updated: Mar 3, 2026

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
Published on: April 28, 2023
1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Abstract:
Naldemedine (Symproic®) is an orally active µ-opioid receptor antagonist being developed by Shionogi & Co., Ltd. that has been approved in the USA and Japan for the treatment of opioid-induced constipation. The drug inhibits peripheral µ-opioid receptors such as those present in the gastrointestinal tract and has minimal or no effect on central opioid activity. This article summarizes the milestones in the development of naldemedine leading to its first global approval in the USA for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Delivery: Enteral Route
FDA Approved Drugs: Changes to Approved Drugs
Drug Nomenclature
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Drug Regulation

